23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort.
AIDS
; 18(8): 1210-3, 2004 May 21.
Article
in En
| MEDLINE
| ID: mdl-15166540
ABSTRACT
23-Valent pneumococcal polysaccharide vaccine was previously reported to be ineffective in HIV-infected Ugandan adults. Prolonged follow-up of trial participants confirmed persistent excess of all-cause pneumonia in vaccine recipients [hazard ratio (HR) 1.6; 95% confidence interval (CI) 1.0-2.4], but surprisingly a survival advantage favouring vaccination (HR 0.84; CI 0.7-1.0). An explanation for the improvement in survival in the face of excess morbid events is lacking; a role for vaccine in HIV care in Africa remains unlikely.
Search on Google
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
HIV Infections
/
AIDS-Related Opportunistic Infections
/
Pneumococcal Vaccines
Type of study:
Clinical_trials
/
Diagnostic_studies
/
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Adult
/
Humans
Country/Region as subject:
Africa
Language:
En
Year:
2004
Type:
Article